22/11/2017 17:42:07

Adamas to Present at Two Upcoming Investor Conferences

Related content
24 May - 
Adamas Announces Publication of Pharmacokinetic Data fo..
09 May - 
Adamas Announces New Employment Inducement Grant
03 May - 
Adamas Reports First Quarter 2018 Financial Results

EMERYVILLE, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:

  • Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 10:30 a.m. ET

  • Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, November 30, 2017 at 8:20 a.m. ET

In addition, the company is scheduled to host meetings at the Global Mizuho Investor Conference on Tuesday, December 5, 2017. 

The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm. Archived versions of the webcasts will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

At Adamas, we believe in the power and promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson’s disease; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information, please visit www.adamaspharma.com.

Contact:

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Youtuber Crypto Crow Inks Deal With TUFF TV to Air New Series to Over 40 Million Homes Beginning First Week of June
2
BODY GLOBE BODY ARMOR® RECEIVES NOTICE OF ALLOWANCE (NOA) NOTICE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HOVERINK BIOTECHNOLOGIES ANNOUNCES.
3
CAST Raises $12.5 Million for Growth Acceleration
4
SHAREHOLDER ALERT: Pomerantz Law Reminds Shareholders with Losses on their Investment in InnerWorkings, Inc. of Class Action Lawsuit and Upcoming Deadline – INWK
5
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synacor, Inc. of Class Action Lawsuit and Upcoming Deadline – SYNC

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
27 May 2018 00:29:01
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180525.2 - EUROWEB2 - 2018-05-27 01:29:01 - 2018-05-27 00:29:01 - 1000 - Website: OKAY